Trial Profile
A prospective open label study to evaluate vasomotor symptoms control and bleeding patterns with a continuous regimen of a new progestin trimegestone 0.125 mg and 17 b estradiol 1 mg (Totelle), as HT [hormone therapy] on postmenopausal women
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Estradiol/trimegestone (Primary)
- Indications Vasomotor symptoms
- Focus Therapeutic Use
- Sponsors Wyeth
- 11 Dec 2007 Status changed from in progress to completed.
- 23 Jul 2007 Status change
- 31 Oct 2006 New trial record.